Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Bone ; 54(1): 83-91, 2013 May.
Article in English | MEDLINE | ID: mdl-23369989

ABSTRACT

Diastrophic dysplasia (DTD) is a chondrodysplasia caused by mutations in the SLC26A2 gene, leading to reduced intracellular sulfate pool in chondrocytes, osteoblasts and fibroblasts. Hence, proteoglycans are undersulfated in the cartilage and bone of DTD patients. To characterize the bone phenotype of this skeletal dysplasia we used the Slc26a2 knock-in mouse (dtd mouse), that was previously validated as an animal model of DTD in humans. X-rays, bone densitometry, static and dynamic histomorphometry, and in vitro studies revealed a primary bone defect in the dtd mouse model. We showed in vivo that this primary bone defect in dtd mice is due to decreased bone accrual associated with a decreased trabecular and periosteal appositional rate at the cell level in one month-old mice. Although the osteoclast number evaluated by histomorphometry was not different in dtd compared to wild-type mice, urine analysis of deoxypyridinoline cross-links and serum levels of type I collagen C-terminal telopeptides showed a higher resorption rate in dtd mice compared to wild-type littermates. Electron microscopy studies showed that collagen fibrils in bone were thinner and less organized in dtd compared to wild-type mice. These data suggest that the low bone mass observed in mutant mice could possibly be linked to the different bone matrix compositions/organizations in dtd mice triggering changes in osteoblast and osteoclast activities. Overall, these results suggest that proteoglycan undersulfation not only affects the properties of hyaline cartilage, but can also lead to unbalanced bone modeling and remodeling activities, demonstrating the importance of proteoglycan sulfation in bone homeostasis.


Subject(s)
Bone Development/physiology , Bone Remodeling/physiology , Proteoglycans/metabolism , Sulfur/metabolism , Aging/blood , Aging/pathology , Aging/urine , Animals , Bone Density , Bone Resorption/blood , Bone Resorption/complications , Bone Resorption/pathology , Bone Resorption/physiopathology , Bone and Bones/metabolism , Bone and Bones/pathology , Bone and Bones/physiopathology , Bone and Bones/ultrastructure , Calcium/blood , Cell Differentiation , Collagen/metabolism , Collagen/ultrastructure , Dwarfism/blood , Dwarfism/complications , Dwarfism/metabolism , Dwarfism/physiopathology , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Organ Size , Osteoclasts/metabolism , Osteoclasts/pathology , Parathyroid Hormone/blood
2.
Hum Mol Genet ; 14(22): 3389-96, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-16204352

ABSTRACT

Osteoporosis is one of the most common degenerative diseases. It is characterized by reduced bone mineral density (BMD) with an increased risk for bone fractures. There is a substantial genetic contribution to BMD, although the genetic factors involved in the pathogenesis of human osteoporosis are largely unknown. Mice with a targeted deletion of either the cannabinoid receptor type 1 (Cnr1) or type 2 (Cnr2) gene show an alteration of bone mass, and pharmacological modification of both receptors can regulate osteoclast activity and BMD. We therefore analyzed both genes in a systematic genetic association study in a human sample of postmenopausal osteoporosis patients and matched female controls. We found a significant association of single polymorphisms (P = 0.0014) and haplotypes (P = 0.0001) encompassing the CNR2 gene on human chromosome 1p36, whereas we found no convincing association for CNR1. These results demonstrate a role for the peripherally expressed CB2 receptor in the etiology of osteoporosis and provide an interesting novel therapeutical target for this severe and common disease.


Subject(s)
Osteoporosis/genetics , Receptor, Cannabinoid, CB2/genetics , Animals , Base Sequence , Case-Control Studies , Chromosomes, Human, Pair 1 , Female , Humans , Mice , Middle Aged , Molecular Sequence Data , Polymorphism, Single Nucleotide , Receptor, Cannabinoid, CB1/genetics
3.
J Bone Miner Res ; 20(5): 799-808, 2005 May.
Article in English | MEDLINE | ID: mdl-15824853

ABSTRACT

UNLABELLED: Chronic thiazide treatment is associated with high BMD. We report that patients and mice with null mutations in the thiazide-sensitive NaCl cotransporter (NCC) have higher renal tubular Ca reabsorption, higher BMD, and lower bone remodeling than controls, as well as abnormalities in Ca metabolism, mainly caused by Mg depletion. INTRODUCTION: Chronic thiazide treatment decreases urinary Ca excretion (UVCa) and increases BMD. To understand the underlying mechanisms, Ca and bone metabolism were studied in two models of genetic inactivation of the thiazide-sensitive NaCl cotransporter (NCC): patients with Gitelman syndrome (GS) and Ncc knockout (Ncc(-/-)) mice. MATERIALS AND METHODS: Ca metabolism was analyzed in GS patients and Ncc(-/-) mice under conditions of low dietary Ca. BMD was measured by DXA in patients and mice, and bone histomorphometry was analyzed in mice. RESULTS: GS patients had low plasma Mg. They exhibited reduced UVCa, but similar serum Ca and GFR as control subjects, suggesting increased renal Ca reabsorption. Blood PTH was lower despite lower serum ionized Ca, and Mg repletion almost corrected both relative hypoparathyroidism and low UVCa. BMD was significantly increased in GS patients at both lumbar (+7%) and femoral (+16%) sites, and osteocalcin was reduced. In Ncc(-/-) mice, serum Ca and GFR were unchanged, but UVCa was reduced and PTH was elevated; Mg repletion largely corrected both abnormalities. Trabecular and cortical BMD were higher than in Ncc(+/+) mice (+4% and +5%, respectively), and despite elevated PTH, were associated with higher cortical thickness and lower endosteal osteoclastic surface. CONCLUSIONS: Higher BMD is observed in GS patients and Ncc(-/-) mice. Relative hypoparathyroidism (human) and bone resistance to PTH (mice), mainly caused by Mg depletion, can explain the low bone remodeling and normal/low serum Ca despite increased renal Ca reabsorption.


Subject(s)
Benzothiadiazines , Bone Density , Kidney Diseases/genetics , Kidney/metabolism , Sodium Chloride Symporter Inhibitors/pharmacology , Symporters/chemistry , Thiadiazines/pharmacology , Adolescent , Adult , Age Factors , Aged , Animals , Body Weight , Bone and Bones/metabolism , Calcium/metabolism , Case-Control Studies , Diuretics , Female , Humans , Hypoparathyroidism , Magnesium/blood , Magnesium/metabolism , Male , Mice , Mice, Knockout , Mice, Transgenic , Middle Aged , Mutation , Phenotype , Sodium Chloride/pharmacology , Sodium Chloride Symporters , Symporters/metabolism , Syndrome , Tibia/metabolism , Time Factors , Transgenes
4.
J Bone Miner Res ; 19(5): 811-22, 2004 May.
Article in English | MEDLINE | ID: mdl-15068505

ABSTRACT

UNLABELLED: Mice specifically overexpressing TIMP-1 in osteoblasts have been generated to investigate the role of MMPs in bone in vivo. These mice displayed increased trabecular bone volume and decreased bone turnover. This model provides evidence of the role played by the MMPs in bone remodeling and balance. INTRODUCTION: Although it has been suggested that the matrix metalloproteinases (MMPs) may play a role in initiating the bone resorption process in vitro, there is no evidence that they play any role in in vivo bone maintenance. MATERIALS AND METHODS: We used an artificial promoter specifically driving cells of the osteoblastic lineage to overexpress the tissue inhibitor of MMPs (TIMP-1) cDNA in mice. Densitometric analysis, using DXA and pQCT, and static and dynamic histomorphometry were used to evaluate the bone phenotype both in male and female transgenic mice. We evaluated osteoblastic differentiation using a primary osteoblast culture and osteoclast activity using an ex vivo organ culture. RESULTS AND CONCLUSION: We showed that at 1 and 2.5 months of age, only the female mice exhibited a bone phenotype. These mice displayed specific increases in the BMD and bone volume of trabecular bone. This increase was accompanied by decreased trabecular separation, suggesting a decrease in bone resorption. Using an ex vivo resorption assay, we demonstrated that parathyroid hormone (PTH)-stimulated bone resorption was reduced in these mice. Evaluation of the bone histomorphometric dynamic parameters showed that the mineralizing surfaces and bone formation rate were both reduced. There was no change in the mineralization lag time or number of osteocyte lacunae. Using primary osteoblast culture and molecular analysis, we showed that the differentiation and function of osteoblasts from transgenic mice were normal, but that the ex vivo formation of mineralized nodules was delayed. This model is the first to show that in vivo MMPs play a role in bone remodeling and bone balance. Moreover, our data suggest that MMP activity could be involved in the hormonal regulation of bone resorption by osteoblasts.


Subject(s)
Bone and Bones/metabolism , Metalloproteases/antagonists & inhibitors , Osteoblasts/enzymology , Tissue Inhibitor of Metalloproteinase-1/metabolism , Alkaline Phosphatase/metabolism , Animals , Bone Density/physiology , Bone Resorption/metabolism , Bone and Bones/diagnostic imaging , Bone and Bones/ultrastructure , Cells, Cultured , Female , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Osteoblasts/cytology , Osteoblasts/metabolism , Phenotype , Promoter Regions, Genetic , Protease Inhibitors/metabolism , Radiography , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinase-1/physiology
5.
Eur Cytokine Netw ; 13(1): 39-45, 2002.
Article in English | MEDLINE | ID: mdl-11956019

ABSTRACT

Estrogen (E2) deficiency is responsible for increased bone turnover in the postmenopausal period, and it can be prevented by estrogen replacement therapy. The way estrogen acts on bone cells is not fully understood. Human bone marrow cell cultures may be a reliable model for studying the action of steroids on osteoclastogenesis in vitro. We examine the effects of estradiol and Raloxifene, a selective estrogen receptor modulator, on human primary bone marrow cells cultured for 15 days. 17beta-estradiol and Raloxifene significantly decreased the number of tartrate-resistant acid phosphatase multinucleate cells from osteoclast precursors on day 15. Estrogen receptor alpha (ER-alpha) mRNA was present in bone marrow mononuclear cells cultured for 5 days, but there was no estrogen receptor beta (ER-beta) mRNA, suggesting that this effect was mediated by ER-alpha. 15-day cultures no longer contained ER-alpha mRNA, suggesting that estrogen acts on early events of osteoclast differentiation. Finally, 10-8 M 17beta-estradiol has no effect on the release of IL-6 and IL-6-sr into the medium of marrow mononuclear cells cultured for 5 or 15 days. Osteoclast apoptosis was not affected by estradiol or Raloxifene after 15 days of culture under our conditions. In conclusion, we have shown that both estradiol and Raloxifene inhibit osteoclast differentiation in human bone marrow mononuclear cultures. The biological effect that can mimic in vivo differentiation could be mediated through ER-alpha.


Subject(s)
Bone Marrow Cells/drug effects , Cell Differentiation/physiology , Estradiol/pharmacology , Osteoclasts/drug effects , Raloxifene Hydrochloride/pharmacology , Receptors, Estrogen/metabolism , Apoptosis/physiology , Bone Marrow Cells/cytology , Cells, Cultured , Estrogen Receptor alpha , Estrogen Receptor beta , Humans , Interleukin-6/metabolism , Osteoclasts/cytology , RNA, Messenger/biosynthesis , Receptors, Estrogen/genetics , Receptors, Interleukin , Receptors, Interleukin-6 , Recombinant Fusion Proteins/metabolism , Selective Estrogen Receptor Modulators/pharmacology , Stem Cells/cytology , Stem Cells/drug effects
6.
Nephrol Dial Transplant ; 17(3): 449-54, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11865091

ABSTRACT

BACKGROUND: Osteomalacia is now a rare disease in dialysis patients in developed countries since the withdrawal of aluminium overload. The involvement of fluoride and strontium in the pathogenesis of the disease has been suggested. The aim of this study was to investigate a possible association between osteomalacia in dialysis patients and the fluoride or strontium contents of bone. METHODS: Of 271 bone biopsies from chronic haemodialysis patients referred to our centre, we studied the nine biopsies from patients with osteomalacia. They were compared with 23 biopsies from patients with hyperparathyroidism and 24 biopsies from patients with adynamic bone disease. Histomorphometric static and dynamic indices were measured. Bone fluoride and strontium contents were measured in biopsies from haemodialysis patients, and were compared with those of control patients. RESULTS: In the nine patients with osteomalacia, we found an absence of double labelled surfaces and increased osteoid thickness. Mild aluminium overload was observed in two of the nine patients. The bone strontium content of the entire dialysis population studied was not significantly different from control values (0.023+/-0.001 vs 0.019+/-0.002% mol/mol, P=0.15). However, bone strontium level was slightly but significantly increased in patients with osteomalacia (0.030+/-0.005%), compared with both controls (0.019+/-0.002%, P<0.05) and the other bone diseases (0.021+/-0.002%, P<0.05). Bone fluoride content was significantly higher in the entire dialysis population than in the controls (0.33+/-0.04 vs 0.13+/-0.018% (g/g ash weight), P=0.04). It was increased in osteomalacic patients compared with controls and with patients having hyperparathyroidism or adynamic bone disease. There was no correlation between formation indices (OV/BV, OS/BS, Ob.S/BS) and bone fluoride or strontium content. CONCLUSIONS: We found a prevalence of osteomalacia of 3.3% in our biopsy series for chronic dialysis patients. However, although bone strontium and fluoride contents were slightly increased, no causal relationship with these individual metals and osteomalacia could be firmly established in this small number of patients. The hypothesis of strontium- or fluoride-induced osteomalacia in renal patients merits further investigation.


Subject(s)
Bone and Bones/metabolism , Fluorides/metabolism , Osteomalacia/etiology , Osteomalacia/metabolism , Renal Dialysis/adverse effects , Strontium/metabolism , Case-Control Studies , Chronic Kidney Disease-Mineral and Bone Disorder/etiology , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Humans , Hyperparathyroidism/metabolism , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...